Hello, Fool! | Login | Signup | My Fool
Dec 2, 2008 1:29 AM ET | Feedback | Site Changes | Help
A biotechnology company dedicated to making an impact on the lives of people with serious diseases. Its product and service portfolio is focused on rare disorders, renal diseases, orthopaedics, organ transplant, and diagnostic and predictive testing.
View Ticker Page (GENZ)
Results 21 - 30 of 41 : 12345
Recs
Beacon10 (23.69) Submitted: 10/03/08 7:57 PM : Start Price: $76.59 GENZ Score: -1.29
Good Massachusetts company. Biotech will disappear quickly if not successful. Genzyme is a good company that has been around for a little while. I love the amount of research they do and its for a great cause. I wish I bought in earlier. There is sti...
Report this Post Replies: 0 | Reply | Permalink
Oops! There appears to be a problem with your comment. Check to see if there's something you left out.
zzlangerhans (99.32) Submitted: 11/26/08 11:45 AM : Start Price: $64.95 GENZ Score: -5.70
I want to take advantage of the downturn and pick up some quality stocks at depressed prices, but I don't want to sacrifice my pure biotech profile. Therefore, I'm branching out into large profitable biotech companies even though I don't really have ...
WilliamCrook2007 (< 20) Submitted: 11/20/08 2:47 PM : Start Price: $68.17 GENZ Score: -19.31
ibd
RNZ100 (< 20) Submitted: 10/08/08 8:24 PM : Start Price: $69.50 GENZ Score: 0.59
Oversold (but then again, what isn't?!)
ramgee (40.32) Submitted: 11/11/08 5:31 PM : Start Price: $69.06 GENZ Score: -9.53
Has held well during this stressed time. New partners with new ideas.
Pablocruz (35.86) Submitted: 3/13/08 3:28 PM : Start Price: $74.07 GENZ Score: 15.80
Short term pop to the up side, then down after fed rate cuts fade in the minds of investors.
samr123 (34.20) Submitted: 12/27/06 3:43 AM : Start Price: $62.40 GENZ Score: 34.59
One of the few profitable biotechs out there. It's the dominant player in many small but life-threatening disease niches. Also has growing diagnostics and medical device businesses.
Niessenwr (< 20) Submitted: 1/04/07 12:31 PM : Start Price: $65.65 GENZ Score: 29.70
Strong capabilities focused on niche market for rare disorders will succeed . . . especially with new salient into stem cell products.
jkotler001 (42.20) Submitted: 2/21/07 9:02 AM : Start Price: $65.59 GENZ Score: 31.58
It will weather stock market downturn in coming year or two.
flampe (93.76) Submitted: 3/19/07 8:59 AM : Start Price: $59.66 GENZ Score: 37.75
CRAMER PICK 3/14
Terms & Conditions
RSS Headlines
Fool UK